

Scientific Program as of April 3, 2025

FRIDAY, A	FRIDAY, APRIL 4, 2025				
08:30-10:00	BIG CONTROVERSIES IN RETINA AND BEYOND IN 2025	HALL A			
Chaire	Particle Kumparmann IICA: Anat Lacutanatain Javasi; Patricia IIdaanda Chain				
Chairs:	Baruch Kuppermann, USA; Anat Loewenstein, Israel; Patricia Udaondo, Spain				
08:30-08:40	Welcome Remarks				
	Baruch Kuppermann, USA; Anat Loewenstein, Israel; Patricia Udaondo, Spain				
08:40-09:00	Keynote Lecture:				
08:40-08:55	Retinal Implants to Restore Vision				
	Mark Humayun, USA				
08:55-09:00	Q&A				
09:00-09:30	Debate 1: Will topical therapy become the standard of care for either prevention or delay of myopia progression?				
09:00-09:10	Yes: Andrzej Grzybowski, Poland				
09:10-09:20	No: <u>Hakan Kaymak</u> , Germany				
09:20-09:30	Discussion				
09:30-10:00	Debate 2: Gene Therapy for NVAMD will be the preferred therapy in the future				
09:30-09:40	Yes: Luis Arias, Spain				
09:40-09:50	No: Paolo Lanzetta, Italy				
09:50-10:00	Discussion				
10:00-10:30	Coffee Break, Visit Exhibition, View ePosters & join us in the Speaker's Corner	EXHIBITION AREA			



	HALL A		HALL B
10:30-12:00	MEDICAL RETINA 1 Neovascular ("Wet") AMD Management	10:30-12:00	GLAUCOMA 1
Chairs:	<u>Luis Arias, Spain; Francesco Bandello,</u> Italy; <u>Rufino Silva,</u> Portugal	Chairs:	Francesca Cordeiro, UK, Marta Pazos, Spain
10:30-11:00	Debate 1: New generation anti-VEGF agents are specifically beneficial for pigment epithelial detachment	10:30-11:00	Debate 1: Phaco alone is better than Phaco Plus MIGS
10:30-10:40	Yes: Francesco Bandello, Italy	10:30-10:40	Yes: Joel Suarez, Spain
10:40-10:50	No: Patricia Udaondo, Spain	10:40-10:50	No: Marta Pazos, Spain
10:50-11:00	Discussion	10:50-11:00	Discussion
11:00-11:30	Debate 2: Home monitoring has the potential to improve patient outcome in AMD	11:00-11:30	Debate 2: Clinicians decisions are better than Al decisions in Glaucoma
11:00-11:10	Yes: Nancy Holekamp, USA	11:00-11:10	Yes: Francesca Cordeiro, UK
11:10-11:20	No: Rodrigo Abreu Gonzalez, Spain	11:10-11:20	No: Marta Pazos, Spain
11:20-11:30	Discussion	11:20-11:30	Discussion
11:30-12:00	Debate 3: Sustained drug delivery has a potential to be a significant treatment option for neovascular AMD and other retinal diseases	11:30-12:00	Debate 3: Preventing Glaucoma is possible and feasible
11:30-11:40	Yes: Dan Martin , USA	11:30-11:40	Yes: Francesca Cordeiro, UK
11:40-11:50	No: Lloyd Clark, USA	11:40-11:50	No: Francesco Oddone, Italy
11:50-12:00	Discussion	11:50-12:00	Discussion
12:15-13:15	Industry Sponsored Luncheon Symposium (Lunch boxes served 12:00-12:15)		
13:30-14:30	Industry-Sponsored Dessert Symposium (Dessert boxes served 13:15-13:30) HALL A		
14:30-15:00	Coffee Break, Visit Exhibition, View ePosters		EXHIBITION AREA



	HALL A		HALL B
15:00-16:30	SURGICAL RETINA 1 Controversial Approaches to Common Surgical Questions	15:00-16:30	GLAUCOMA 2
Chairs:	William F. Mieler, USA, Jose Garcia-Arumi, Spain, Young Hee Yoon, Korea	Chairs:	Francesca Cordeiro, UK, Joel Suarez, Spain
15:00-15:30	Debate 1: Inverted flap technique is the best surgical approach for large recurrent macular holes in high myopes	15:00-15:30	Debate 1: Should Glaucoma be managed by comprehensiv ophthalmologists or Glaucoma specialists?
15:00-15:10	Yes: Zofia Anna Nawrocka, Poland	15:00-15:10	Yes: Joel Suarez, Spain
15:10-15:20	No: Jose Garcia-Arumi, Spain	15:10-15:20	No: Jose Belda, Spain
15:20-15:30	Discussion	15:20-15:30	Discussion
15:30-16:00	Debate 2: In the setting of a phakic macula-on retinal detachment, with a superior retinal tear, comparable successful anatomic and visual outcomes can be achieved with either a vitrectomy, or with a scleral buckle	15:30-16:00	Debate 2: Glaucoma drops should be Preservative Free from first line
15:30-15:40	Yes: Zofia Anna Nawrocka, Poland	15:30-15:40	Yes: Jose Belda, Spain
15:40-15:50	No: Diego Ruiz Casas, Spain	15:40-15:50	No: Antonio Ferreras, Spain
15:50-16:00	Discussion	15:50-16:00	Discussion
16:00-16:30	Debate 3: Pars plana vitrectomy is safe and effective in the management of symptomatic vitreous floaters	16:00-16:30	Debate 3: Tradition or Innovation? Trabeculectomy versus Minimally Invasive Bleb-based surgeries.
16:00-16:10	Yes: Isabel Relimpio, Spain	16:00-16:10	Tradition: Antonio Fea, Italy
16:10-16:20	No: William F. Mieler, USA	16:10-16:20	Innovation: Sheng Lim, UK
16:20-16:30	Discussion	16:20-16:30	Discussion



FRIDAY, AF	PRIL 4, 2025
16:30-17:30	VISION ACADEMY IN RETINA 2025 New challenges within retinal diseases: Navigating the evolving treatment landscape
Chairs:	Anat Loewenstein, Israel; Baruch Kuppermann, USA
16:30-16:35	Introduction to the Vision Academy Baruch Kuppermann, USA
16:35-16:50	 Rapid-fire presentations: Impact of residual retinal fluid on treatment outcomes in nAM) - <u>Dinah Zur</u>, Israel Diagnosis and assessment of simultaneous GA and CNV/MNV - <u>Paolo Lanzetta</u>, Italy Cataract surgery and anti-VEGF management – <u>Francesco Bandello</u>, Italy
16:50-17:00	Q&A Moderators: Anat Loewenstein, Israel; Baruch Kuppermann, USA
17:00-17:25	Panel discussion / Q&A: Expert opinion on the use of new treatment regimens with extended injection intervals Moderators: Anat Loewenstein, Israel; Baruch Kuppermann, USA Panelists: Dinah Zur, Israel Francesco Bandello, Italy Jean Francois Korobelnik, France Paolo Lanzetta, Italy Group discussion: All
17:25-17:30	Session close Anat Loewenstein, Israel
17:30-18:30	Industry Sponsored Symposium
18:30-19:30	Welcome Reception
	End of Day



SATURDAY	7, APRIL 5, 2025		
07:30-08:30	Industries Sponsored Breakfast Symposium		HALL A
	(Light breakfast will be served from 07:00-07:30 at the entrance of the	hall)	
	HALL A		HALL B
08:30-10:00	MEDICAL RETINA 2 Diabetic Macular Edema (DME) and Proliferative Diabetic Retinopathy	08:30-10:00	NEURO-OPHTHALMOLOGY 1 The Afferent Pathway
Chairs:	Francesco Bandello, Italy, Jose Maria Ruiz Moreno, Spain; Rufino Silva, Portugal	Chair:	Andrew G. Lee, USA
08:30-09:00	Debate 1: Steroid Therapy for DME is still relevant in the Era of New Generation Anti-VEGF agents	08:30-09:00	Debate 1: All acute ON patients require high dose corticosteroids
08:30-08:40	Yes: Francesco Bandello, Italy	08:30-08:40	Yes: Andrew G. Lee, USA
08:40-08:50	No: <u>Juan Donate Lopez</u> , Spain	08:40-08:50	No: Dan Milea , France
08:50-09:00	Discussion	08:50-09:00	Discussion
09:00-09:30	Debate 2: Oral Therapy for NPDR will be adopted as primary approach to management of NPDR	09:00-09:30	Debate 2: Temporal artery (TA) ultrasound should replace TA biopsy in GCA
09:00-09:10	Yes: <u>David M. Brown</u> , USA	09:00-09:10	Yes: Susan Mollan, UK
09:10-09:20	No: Jorge Ruiz Medrano, Spain	09:10-09:20	No: Andrew G. Lee, USA
09:20-09:30	Discussion	09:20-09:30	Discussion
09:30-10:00	Debate 3: Novel topical steroids will become standard or care for initial therapy in mild DME	09:30-10:00	Case Presentations: Afferent Moderator: Andrew G. Lee, USA
09:30-09:40	Yes: Baruch Kuppermann, USA		Panelists: All Speakers
09:40-09:50	No: Francesco Boscia, Italy		
09:50-10:00	Discussion		
10:00-10:30	Coffee Break, Visit Exhibition, View ePosters & join us in the Spe	akers' Corner	EXHIBITION AREA



	HALL A		HALL B
10:30-12:00	MEDICAL RETINA 3 Novel Technologies and Therapies in Retinal Diseases	10:30-12:00	UVEITIS 1
Chairs:	<u>Dinah Zur</u> , Israel; <u>Maribel Lopez Galvez</u> , Spain; <u>Enrique Rodriguez de la Rua</u> , Spain	Chairs:	Bahram Bodaghi, France; Zohar Habot-Wilner, Israel
10:30-11:00	Debate 1: Multi-pathway or high dose inhibitors improve DME biomarkers more than previous treatments	10:30-11:00	Debate 1: The use of biosimilars in uveitis
10:30-10:40	Yes: Enrique Rodriguez de la Rua, Spain	10:30-10:40	Yes: Zohar Habot-Wilner, Israel
10:40-10:50	No: <u>Dinah Zur</u> , Israel	10:40-10:50	No: Sofia Androudi, Greece
10:50-11:00	Discussion	10:50-11:00	Discussion
11:00-11:30	Debate 2: Existing outcome measures are sufficient to demonstrate the efficacy of new therapies for inherited retinal diseases	11:00-11:30	Debate 2: Prophylactic laser retinopexy and early pars plana vitrectomy (PPV) for preventing retinal detachment (RD) in acute retinal necrosis
11:00-11:10	Yes: Enrique Rodriguez de la Rua, Spain	11:00-11:10	Yes: Alfredo Adán Civera, Spain
11:10-11:20	No: Dinah Zur, Israel	11:10-11:20	No: Sofia Androudi, Greece
11:20-11:30	Discussion	11:20-11:30	Discussion
11:30-12:00	Debate 3: Blocking more than VEGFA can help in improving visual acuity in retinal disease	11:30-12:00	Debate 3: HLA - testing is mandatory in the investigation of posterior uveitis
11:30-11:40	Yes: Young Hee Yoon, Korea	11:30-11:40	Yes: Bahram Bodaghi, France
11:40-11:50	No: <u>Luis Arias</u> , Spain	11:40-11:50	No: Ester Carreño, Spain
11:50-12:00	Discussion	11:50-12:00	Discussion
12:15-13:15	Industry-Sponsored Luncheon Symposium (Lunch boxes served 12:00-12:15)		HALL A
13:30-14:30	Industries Sponsored Dessert Symposium (Dessert boxes served 13:15-13:30)		HALL A
14:30-15:00	Coffee Break, Visit Exhibition, View ePosters & join us in the Spe	akers' Corner	EXHIBITION AREA



	HALL A		HALL B
15:00-16:30	SURGICAL RETINA 2 Controversies in the Utilization of Cutting Edge Vitreoretinal Surgical Technology	15:00-16:30	NEURO-OPHTHALMOLOGY 2 The Efferent Pathway
Chairs:	William F. Mieler, USA, <u>Jose Maria Ruiz-Moreno</u> , Spain Mark Humayun, USA	Chair:	Andrew G. Lee, USA
15:00-15:30	Debate 1: Artificial Intelligence (AI) can predict the success of retinal detachment surgery	15:00-15:30	Debate 1: Functional visual loss is an organic disease
15:00-15:10	Yes: Stanislao Rizzo, Italy	15:00-15:10	Yes: Susan Mollan, UK
15:10-15:20	No: Francesco Boscia, Italy	15:10-15:20	No: Dan Milea , France
15:20-15:30	Discussion	15:20-15:30	Discussion
15:30-16:00	Debate 2: Heavy silicone is the most beneficial adjuvant in the successful management of a retinal detachment with proliferative vitreoretinopathy (PVR)	15:30-16:00	Debate 2: IIH is a medical not surgical disease now
15:30-15:40	Yes: Stanislao Rizzo, Italy	15:30-15:40	Yes: Susan Mollan, UK
15:40-15:50	No: <u>Jose Garcia-Arumi</u> , Spain	15:40-15:50	No: Andrew G. Lee, USA
15:50-16:00	Discussion	15:50-16:00	Discussion
16:00-16:30	Debate 3: Multifocal or Extended Depth of Focus (EDOF) IOLs can be employed after successful repair of a macula-off retinal detachment	16:00-16:30	Case Presentations: Efferent Moderator. Susan Mollan, UK
16:00-16:10	Yes: William Mieler, USA		Panelists: All Speakers
16:10-16:20	No: Mari Carmen Desco, Spain		
16:20-16:30	Discussion		



	HALL A		HALL B
16:30-18:00	MEDICAL RETINA 4 New Treatment Strategies	16:30-18:00	UVEITIS 2
Chairs:	Michaella Goldstein, Israel; Esther Ciancas, Spain;	Chairs:	Bahram Bodaghi, France; Zohar Habot-Wilner, Israel
16:30-17:00	Debate 1: Functional outcomes need to be used for assessment of treatment effects of drugs for non neovascular Age Related Macular Degeneration	16:30-17:00	Debate 1: Systemic therapy is the best option to control uveitic macular edema
16:30-16:40	Yes: Michaella Goldstein, Israel	16:30-16:40	Yes: Alejandro Fonollosa Calduch, Spain
16:40-16:50	No: Jean-Francois Korobelnik, France	16:40-16:50	No: Zohar Habot-Wilner, Israel
16:50-17:00	Discussion	16:50-17:00	Discussion
17:00-17:30	Debate 2: Photobiomodulation is a viable treatment in non neovascular AMD	17:00-17:30	Debate 2: Post-operative macular edema may be considered and managed as a uveitis
17:00-17:10	Yes: David Almeida , USA	17:00-17:10	Yes: Bahram Bodaghi, France
17:10-17:20	No: <u>Jordi Monés</u> , Spain	17:10-17:20	No: Alfredo Adán Civera, Spain
17:20-17:30	Discussion	17:20-17:30	Discussion
17:30-18:00	Debate 3: Complement inhibition for geographic atrophy has more benefit than risk	17:30-18:00	Debate 3: Inflammatory choroidal neovascularization may be treated by anti-VEGFs alone
17:30-17:40	Yes: Jordi Monés, Spain	17:30-17:40	Yes: Alejandro Fonollosa Calduch, Spain
17:40-17:50	No: <u>Jean-Francois Korobelnik</u> , France	17:40-17:50	No: Ester Carreño, Spain
17:50-18:00	Discussion	17:50-18:00	Discussion